OR WAIT null SECS
November 02, 2021
Aceragen’s acquisition of Arrevus adds key treatment candidates to its rare disease pipeline.
Novartis’ scemblix (asciminib) is designed to provide a single treatment option to patients struggling with chronic myeloid leukemia.
Following the acquisition, Avantor will have access to Masterflex’s various bioproduction operations.
November 01, 2021
Abbvie’s Vuity (pilocarpine HCI ophthalmic solution) is the first and only eye drop to receive FDA approval for the treatment of presbyopia.
The Pfizer-BioNTech COVID-19 vaccine is the first to receive FDA Emergency Use Authorization for use in children ages five to 11.
October 29, 2021
The research collaboration between Sartorius and Matica Biotechnology will aim to optimize PAT technologies, automation software, and single-use platforms for large-scale viral vector production.
Novavax has filed its COVID-19 vaccine for authorization in the UK and Australia.
EMA’s CHMP concluded that a booster dose of Moderna’s Spikevax vaccine may be considered in people aged 18 and older.
Genentech’s Susvimo (ranibizumab injection) is approved for intravitreal use via ocular implant for the treatment of neovascular age-related macular degeneration.
Becton, Dickinson, and Company and partner Aptar’s new plunger stopper will support the injection of biologics into subcutaneous tissue.